Annular atrophic lichen planus induced by anti-HER2 antibodies.
Australas J Dermatol
; 62(2): 210-212, 2021 May.
Article
em En
| MEDLINE
| ID: mdl-33216943
ABSTRACT
Pertuzumab and trastuzumab are monoclonal antibody inhibitors targeting human epidermal growth factor receptor 2 (HER-2) and are increasingly being utilised in the management of HER2-positive breast cancer, having been demonstrated to improve progression-free survival in conjunction with docetaxel. We present a rare presentation of a lichenoid drug eruption, in an annular atrophic variant, in a 35-year-old woman after initiation of HER2-inhibitor (pertuzumab and trastuzumab) therapy for metastatic breast cancer.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Receptor ErbB-2
/
Antineoplásicos Imunológicos
/
Líquen Plano
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article